Our systems have detected that you are using a computer with an IP address located in the USA.
If you are currently not located in the USA, please click “Continue” in order to access our Website.

Local restrictions - provision of cross-border services

Swissquote Bank Ltd (“Swissquote”) is a bank licensed in Switzerland under the supervision of the Swiss Financial Market Supervisory Authority (FINMA). Swissquote is not authorized as a bank or broker by any US authority (such as the CFTC or SEC) neither is it authorized to disseminate offering and solicitation materials for offshore sales of securities and investment services, to make financial promotion or conduct investment or banking activity in the USA whatsoever.

This website may however contain information about services and products that may be considered by US authorities as an invitation or inducement to engage in investment activity having an effect in the USA.

By clicking “Continue”, you confirm that you have read and understood this legal information and that you access the website on your own initiative and without any solicitation from Swissquote.

Research Market strategy
by Swissquote Analysts
Live Analysis

Ultragenyx Pharmaceuticals: FDA approvals may boost the price

Ultragenyx Pharmaceuticals is a specialised company in the research, development and commercialisation of drugs for the curing of genetic diseases. The company’s stock is now trading nears its 52-week low. The company has indeed seen of some of its recent researches getting abandoned despite strong investment after trials were not successful.

In November Ultragenyx pharmaceuticals is awaiting for the FDA approval regarding a new molecule rhGUS which has a strong potential. This molecule has had trials that showed good results which is why we believe that the stock price may surge amid the final FDA decision. On top of that the European Union should allow the drug to enter the single market by next year.

According to us, this is a great short-term opportunities. It is of course highly speculative but fundamentals seem to show that the risk potential is asymmetric. Downside risk is very limited while upside can be tremendous.

For the time being, the company will disclose its earnings next Monday 6th of November after the market closes. It may be good to enter the trade the next day hoping that the FDA decision will not be known at that moment.

High/Low /
Live chat